Wednesday, July 22, 2026

North Korea and Russia Strengthen Ties: Key Developments in Healthcare Cooperation

A Russian delegation visited North Korea for the groundbreaking of a Friendship Hospital, enhancing bilateral cooperation in various sectors.

Canon Continues Design Excellence with Five 2025 iF Design Awards

Canon won five prestigious iF Design Awards in 2025, showcasing innovation and sustainability in product design.

THE VILE TRILOGY: Seoul Now Joins Pyongyang and Beijing In A New Axis of Appeasement and Disarmament

The People Power Party criticizes the Lee Jae Myung administration's North Korea policy, calling it a dangerous peace fantasy amid missile provocations.

Tag: ADC

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

LegoChem expands options beyond early ADC licensing into late-stage clinical development

LegoChem Biosciences secures funding to advance ADC therapies into late-stage trials, enhancing strategic flexibility in biotech.

ABL Bio to Showcase Dual-Target ADC Candidate ABL209 at World ADC Korea 2026

ABL Bio will showcase its dual-target ADC candidate ABL209 at the World ADC Korea 2026, focusing on enhanced cancer treatment.

How Dong-A ST’s SC5024 and ADC Innovations Could Change the Game Cancer Pipeline

Dong-A ST showcased its innovative cancer pipeline at AACR 2026, featuring promising preclinical findings and advanced therapeutic strategies.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.